India needs hold carefully communicate with the administration of Bharat Biotech regarding its vaccine, said Joachim Hombach, Executive Secretary for the World Health Organization's (WHO's) Strategic Advisory Group of Experts on Immunisation.
Speaking with CNBC-TV18, Hombach said that the decision to grant emergency use authorisation for Covaxin is a sovereign one, and WHO has no insight on India's emergency use authorisation. Regarding the approval for Pfizer, he explained that the vaccine has been widely tested and India should have good reason for seeking its immunogenicity data.
Moreover, India is set to begin a massive domestic vaccination drive, but has received requests for 20 million doses of the vaccine from neighbouring countries, Latin American nations and African countries. The Ministry of External Affairs is chalking out a plan for export of vaccines to neighbours and key allies.
Many nations including Brazil have signed commercial deals with Serum Institute and Bharat Biotech and recently over 60 envoys visited the Bharat Biotech facility in India. CNBC-TV18 spoke to Ecuador's Ambassador to India Hector Cueva Jacome, who had visited the Bharat Biotech facility and even participated in Covaxin's trials.
To know more, watch the video.